Subscribe
Blinatumomab for B-cell ALL Relapse, IVIG for MIS-C, Review of Irritable Bowel Syndrome, and more

JAMA Editor’s Summary

Blinatumomab for B-cell ALL Relapse, IVIG for MIS-C, Review of Irritable Bowel Syndrome, and more

Editor's Summary by Mary McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the
March 2, 2021

Blinatumomab for B-cell ALL Relapse, IVIG for MIS-C, Review of Irritable Bowel Syndrome, and more

Editor’s Summary by Mary McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the March 2, 2021 issue

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

cover
Cultivating Resilience During Times of Crisis and Existential Threat Keith interviews Dr. Chris Recinos, the CEO and founder of Nurse Leader Network, regarding mental health, adaptive and maladaptive mechanisms of resilience, and conscious self-development.